Local view for "http://purl.org/linkedpolitics/eu/plenary/2001-05-30-Speech-3-018"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2001-05-30"^^xsd:date2
dcterms:Is Part Of	lp_eu:Specific technological R [amp] D programme2
dcterms:Language	"nl"^^xsd:language2
lpv:document identification number	"en.20010530.4.3-018"2
lpv:hasSubsequent	lp_eu:2001-05-30-Speech-3-0192
lpv:speaker	lp:W.G. van Velzen2
lpv:spokenAs	vice-chair; EPP-ED (1999-09-30--2004-07-19)3 member; Delegation to the EU-Poland Joint Parliamentary Committee (1999-10-06--2002-01-14)3 unknown; Christen Democratisch Appèl (1999-07-20--2004-07-19)3 member; Committee on Industry, External Trade, Research and Energy (1999-07-21--2002-01-14)3 substitute; Delegation to the EU-Slovak Republic Joint Parliamentary Committee (1999-10-08--2002-01-14)3 substitute; Committee on Foreign Affairs, Human Rights, Common Security and Defence Policy (1999-09-01--2002-01-14)3 member; Temporary committee on the Echelon interception system (2000-07-06--2001-09-05)3
lpv:translated text	"Madam President, I should like to thank the Commissioner warmly for his explanation and particularly for the fact that he managed to adhere to the agreed deadlines. That is a major achievement. I should also like to ask him if he could answer the questions put to him by the Committee on Industry, External Trade, Research and Energy as soon as possible. That will, in turn, enable us to adhere to the deadlines, which is very important in my opinion. I have two explicit questions to put to the Commissioner. Firstly, in the specific programme, the most important research, and thus the money, is earmarked for the human genome and biotechnology. This may be a major area of research, but the results will only become evident over a ten- to fifteen-year period. At present, many EU citizens still die, unfortunately, of the three well-known diseases, namely cancer, heart and vascular diseases, and signs of ageing, such as Alzheimer’s. The Committee on Industry, External Trade, Research and Energy has expressed a growing need for a separate life-science programme within the context of the human genome and biotechnology. I should like to find out from the Commissioner whether he would be prepared to help us think about setting up a programme of this kind. My second question to the Commissioner is of a technical nature: the Commissioner delivered a comprehensive explanation with regard to Article 169 of the Treaty. Why does he not apply Article 168 of the Treaty? Surely that would be a far more practical approach."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph